7. 11. Genetics plays a limited role in ESA-hyporesponsiveness and haemoglobin outcomes in end-stage renal disease patients on haemodialysis. 21. 5. Assessment of Peak Inspiratory Flow Rate in Patients With Chronic Obstructive Pulmonary Disease: Impact on Dose Delivery and Relationship With Response to Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy. 9. Sanofi Pasteur 8008222463 ActHib Adacel Daptacel Fluzone POSTER: Phase 2 study of anti-TIGIT GSK4428859A (GSK859A)/EOS-448 + anti-CD96 GSK6097608 (GSK608) + antiPD-1 dostarlimab in non-small cell lung cancer (NSCLC), 1.POSTER: Prevalence and clinical characteristics of metastatic synovial sarcoma (mSS) patients with tumours expressing NY-ESO-1 antigen (NY+) and who are HLA-A*02:01, *02:05 or *02:06 allele positive (HLA+): Cohort study from the French Sarcoma Group (Presentation Posted With Permission), 1.POSTER: NIRVANA-1: A multicentric randomized trial to compare carboplatin-paclitaxel (CP) followed by niraparib (nira) to CPbevacizumab (bev) followed by nira-bev in patients with stage IIIA/B/C high-grade epithelial ovarian cancer with no residual disease after frontline surgery (Presentation Posted With Permission), 1. Patients with Uncontrolled Asthma Eligible for a Biologic. J Clin Oncol. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: ENGOT-EN6/GOG-3031/ NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin Paclitaxel Versus Placebo + CarboplatinPaclitaxel in Recurrent or Primary Advanced Endometrial Cancer, 7. Practical Use of ELLIPTA, a Once-Daily, Dry Powder Inhaler for Children With Asthma. Tumor necrosis factor receptor superfamily, member 4 (OX40 [CD134]) is expressed by T cells during antigen-specific priming. Das M, Zhu C, Kuchroo VK. CAPTAIN Study: Evaluating the Efficacy of Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI in Inadequately Controlled Asthma Using Change in Asthma Control Questionnaire and the Relationship With Trough FEV1. Seifert L, Werba G, Tiwari S, et al. Ramesh N, Hegewald M, Maselli DJ, et al. Corbridge T, Casale T, Germain G, et al. Prescribing Information GARDASIL9 (Human Papillomavirus 9-valent Vaccine, Recombinant) Storage and Handling M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live) Storage and Handling PedvaxHIB [Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)] Storage and Handling . Bogart M, Germain G, Lalibert F, et al. GSK3377794 is being investigated as a monotherapy and in combination with pembrolizumab in NY-ESO-1 and/or LAGE-1apositive solid tumors, NSCLC, and relapsed/refractory multiple myeloma. Safety and reactogenicity of RZV: Experience from clinical trials and post-marketing. GSK is committed to monitoring the safety of our products and we encourage you or your health care provider to report any side effect or suspected overdose to GSK at 888-825-5249. POSTER: Frequency and impact of retreatment in relapsed refractory multiple myeloma (RRMM): Real-world survey conducted in 5 European Countries (United Kingdom, France, Germany, Italy, Spain), 3. 2017;31(2):101-1261. Lee LA, Boulet LP, Fowler A, et al. Seasonal Efficacy of Mepolizumab in Patients With Severe Eosinophilic Asthma Meta-analysis From Two Phase 3 Trials. Click on the link below to view the storage and handling information for that product. PUBLICATION ONLY: Patient-reported outcomes (PRO) in the GARNET trial in patients (pts) with advanced or recurrent dMMR/MSI-H endometrial cancer (EC) treated with dostarlimab, 24. 801; Abstract A7738]. Prevalence, Regional Distribution, and Trends of Antimicrobial Resistance Among Female Outpatients With Urine Klebsiella pneumoniae Isolates: A Multicenter Evaluation. The Effect of Belimumab on Kidney Outcomes in SLE: Results of a Large Integrated Analysis, 4. Upon receipt, store refrigerated at 2C to 8C (36F to 46F). POSTER: Patient-reported outcomes from the GARNET trial in patients with advanced or recurrent mismatch repair deficient colorectal cancer: a post hoc subgroup analysis, 11. POSTER: Real-World Belantamab Mafodotin (Belamaf) Use: A US Retrospective Longitudinal Pharmacy and Medical Open-Source Claims Database Assessment, 1. Georgiev H, Ravens I, Papadogianni G, Bernhardt G. Coming of age: CD96 emerges as modulator of immune responses. 9. DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 9. Poster No. POSTER: First-line Maintenance Among Advanced Ovarian Cancer Patients in The US Oncology Network: A Real-world Retrospective Cohort Study, 9. Real-world adherence to single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in a commercially insured US population. 4. Sanofi Pasteur 800-822-2463 . Analysis of a Composite Endpoint of Exacerbation and Early Study Treatment Withdrawal in Symptomatic Patients With COPD Free of Inhaled Corticosteroids: A Post Hoc Analysis of the EMAX Trial. Schwarz TF et al. Real-World Impact of Triple Therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control among Patients with Asthma in the US. Zejula [summary of product characteristics]. Real-World Average Dose of PARP Inhibitors Used as Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer, 1. Achieving SLE Disease Control or LLDAS and Lower Organ Damage Rates, 2. Poster No. 3. Please download the thermostability information for full details. Cross-sectional survey to assess the burden of nocturnal symptoms in patients with chronic obstructive pulmonary disease (COPD). Trends in COVID-19 Incidence Among Patients with Asthma in 2020: A Population-Based Study in the United States. POSTER: ENGOT-EN6/NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin-Paclitaxel Versus Placebo + Carboplatin-Paclitaxel in Recurrent or Primary Advanced Endometrial Cancer (EC), 6. Causes of Death in Patients with Anemia of Chronic Kidney Disease (With/Without Diabetes Mellitus) in the ASCEND-ND Trial, 10. POSTER: Master protocol to assess the safety and recommended phase 2 dose of next generation NY-ESO-1specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and non-small cell lung cancer, 1. A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study, 6. POSTER: Real-world clinical outcomes with poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitors as second-line maintenance therapy in patients with recurrent ovarian cancer in the United States[GMA ROYAL study], 1. Poster No. ORAL PRESENTATION: No Evidence of BCMA Expression Loss or Systemic Immune Impairment After Treatment With the BCMA-targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 2. POSTER: Real-world assessment of patients with ovarian cancer who received niraparib as second-line maintenance therapy in the United States: did first-line maintenance approval change the patient profile for second-line maintenance therapy? Molfino NA, Averell CM, Hahn BA, et al. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Poster No. POSTER: Single-agent Belantamab Mafodotin in Patients With Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 trial, 2. Singh AK, et al. NY-ESO-1 based immunotherapy of cancer: current perspectives. P1512. Mepolizumab Reduces Exacerbations and Improves Health-Related Quality of Life in Patients With Severe Asthma and Nasal Polyps, Sinusitis, or Allergic Rhinitis. Bogart M, Chastek B, White J, et al. ORAL PRESENTATION: Bone Marrow Fibrosis Changes Do Not Correlate with Efficacy Outcomes in Myelofibrosis: Analysis of More Than 300 JAK Inhibitor-Nave Patients Treated with Momelotinib or Ruxolitinib, 1. Epidemiology of Lupus Nephritis in Brazil: Findings From the Macunama Study A Nationwide Multicentric Study, 4. Impact of State Residence on Adult Vaccination Uptake: A Multilevel Modeling Approach. POSTER: The Impact of Momelotinib on Patient Reported Quality of Life for Symptomatic and Anemic Patients with Myelofibrosis: Results from the Phase 3 MOMENTUM study, 9. GSK3196165 An investigational anti-GM-CSF monoclonal antibody, improves patient reported outcomes in a phase IIB study of patients with rheumatoid arthritis, 2. Treatment sequencing among asthma patients who were newly treated with long-acting antimuscarinic antagonist (LAMA) in the United States. Tai Y-T, Mayes PA, Acharya C, et al. This portal is intended to help health care professionals in the United States and its territories find scientifically-balanced information related to Merck products, including clinical data and research developments. POSTER: Management of immune-related adverse events in patients with solid tumours treated with dostarlimab in the GARNET study (IGCS ENCORE), 1.POSTER: AGO-OVAR 28 / ENGOT-ov57: Niraparib vs niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial) (Presentation Posted With Permission), 2.POSTER: Characterization of long term survivor and maintenance therapy in relapsed ovarian cancer (CAROLIN)- Intergroup study NOGGO / A-AGO (Presentation Posted With Permission), 3.POSTER: Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33) (Presentation Posted With Permission), 1. POSTER: Marijam A, et al. Poster with video: Long-term Treatment Outcome With Niraparib in Patients With Recurrent Ovarian Cancer: Results From the ENGOT-OV16/NOVA Trial, 3. Headline results for a phase 4, 52-week, randomized, double-blind, placebo-controlled study to assess adverse events of special interest (AESI) in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving belimumab, 1. Singer D et al. Liu M, Bagnasco D, Matucci A, et al. Single-agent Belantamab Mafodotin for RRMM: Analysis of the Lyophilized Presentation Cohort from the Pivotal DREAMM-2 Study [Poster not available for viewing due to copyright restrictions], 9. [Poster No. [Poster No. P372; Abstract A6482]. Stark A-K, Sriskantharjah S, Hessel EM, Okkenhaug K. PI3K inhibitors in inflammation, autoimmunity and cancer. Impact of Prolonged Dose Delays on Response with Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in DREAMM-2 Study: 13-Month Follow-Up, 4. Singh, AK et al. 14. Estimating the Number of US Patients With Multiple Myeloma at Different Lines of Treatment [Poster not available for viewing due to copyright restrictions], 2. 3. Poster No. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. Use this tool to calculate the stability of any GSK vaccine. You are using an unsupported browser.Some features of this site may not function properly. [Poster No. It is being investigated as monotherapy and in combination with other anticancer agents in various malignancies. 7. Tabberer M, von Maltzahn R, Bacci E, et al. 2. 1. MOONSTONE: A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab in Patients With Platinum Resistant Ovarian Cancer (TiP), 5. . 3. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Asthma in the United States: A Population-Based Study. Headline results for a phase 4, 52-week, randomized, double-blind, placebo-controlled study to assess adverse events of special interest (AESI) in adults with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving belimumab. P1505. Coyne DW, et al. Epidemiology of Eosinophilic Granulomatosis with Polyangiitis (EGPA) and Hypereosinophilic Syndrome (HES) in Germany: A Claims Database Study. 4. Brought to you by Merck & Co, Inc., Rahway, NJ, USA (known as MSD outside the US and Canada) dedicated to using leading-edge science to save and improve lives around the world. INTREPID: Clinical Effectiveness of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Versus Multiple-Inhaler Triple Therapy in Usual Clinical Practice. Bintrafusp alfa is a bifunctional fusion protein composed of the extracellular domain of the human transforming growth factor receptor II (TGF-RII or TGF- trap") fused via a flexible linker to the C-terminus of each heavy chain of the IgG1 antibody blocking PD-L1. 8. The host STING pathway at the interface of cancer and immunity. Preliminary Safety, Efficacy, and Pharmacokinetic/Pharmacodynamic Characterization from GARNET, a Phase 1/2 Clinical Trial of the Anti PD 1 Monoclonal Antibody, Dostarlimab, in Patients with Recurrent or Advanced MSI H and MSS Endometrial Cancer (EC), For a copy of a poster please call 1-877-475-6448, 1. Smith E, Zhou W, Shindiapina P, Sif S, Li C, Baiocchi RA. POSTER: Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study (IGCS ENCORE), 12. ORAL PRESENTATION: Safety and efficacy of anti-PD-1 antibody dostarlimab in patients with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study, 1. Characteristics and Inpatient Outcomes of Hospitalized Patients with COVID-19 A Population Study. 2018 Apr;125:76-84. doi: 10.1016/j.ejpb .2018.01. . 493), 3. 14. Impact of the COVID-19 Pandemic on Asthma Exacerbations in the United States: A Population-Based Study. 7. 2. Shareholding calculator. PRMT5 is overexpressed in multiple tumor types, including lymphoma and breast, lung, and bladder cancer, and regulates splicing, gene expression, and activation of p53. 2. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Asthma in the United States: A Population-Based Study. POSTER: The Burden of Illness and the Incremental Burden of Transfusion Dependence in Myelofibrosis in the United States, 11. Please download the thermostability information for full details. ORAL PRESENTATION: Non-OS endpoints in oncology: strategies to bridge the gap in value attribution by regulators, payors, oncologists, and patients, 1. Lee J, Pollard S, Liu M, et al. Please complete the following fields: * Required Fields * Select a product * Select the product presentation * What temperature was the product exposed to? Baseline Platelet Count and Body Weight as Predictors of Early Dose Modification in the QUADRA Trial of Niraparib Monotherapy for the Treatment of Heavily Pretreated (4th Line), Advanced, Recurrent High Grade Serous Ovarian Cancer, 4. Safety of Belimumab in Adult Patients With Systemic Lupus Erythematosus: A Large Integrated Safety Analysis of Controlled Clinical Trial Data, 1. Inactivated vaccines must be kept between 2 and 8C (between 36 and 46F) and not frozen. Amatore F, Gorvel L, Olive D. Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy. 5. Comparison of Peak Inspiratory Flow Rate Between Clinical Trial and Real-World Populations. Verhamme K, de Ridder M, Webb D, et al. ZEJULA [package insert]. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Dostarlimab is a humanized antiPD-1 mAb that binds with high affinity to PD-1 and effectively blocks interactions with PD-L1 and PD-L2. POSTER: Time to next treatment (TTNT) of first-line maintenance (1Lm) niraparib monotherapy in epithelial ovarian cancer (EOC) patients (pts) in the CHAR1ZMA study, 2. Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients in the United States A Population Study. PO0465, 4. 1. Chronic obstructive pulmonary disease is associated with an increased risk of herpes zoster: a retrospective analysis of a United States claims database from 2013-2018. A Randomized, Cross-Over Study Comparing Critical and Overall Errors, Teaching Time, and Preference of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers in Patients with Asthma. Poster No. Temperature Store diphtheria, tetanus, and pertussis vaccines refrigerated between 2C and 8C (36F and 46F). Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Asthma in the United States: A Population-Based Study. Patient-reported outcomes (PRO) in patients receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial ESMO 2020, 2. 4. Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is involved in driving necroptosis, a proinflammatory form of cell death that may promote metastasis and suppress T-celldriven antitumor immunity. Real-World Effectiveness Of Mepolizumab In Patients With Allergic And Non-Allergic Asthma. 1. Bintrafusp alfa is designed to allow for targeting tumor cells via two nonredundant immunostimulatory mechanismsthe TGF- and PD-L1 pathways. P805; Abstract A7742]. Associations between haemoglobin values and rate of changes with MACE in the ASCEND-ND randomised clinical trial. Poly ADP ribose polymerases (PARPs) are a family of enzymes involved in many functions, including DNA repair, gene expression, cellular signaling, and base excision repairs. POSTER: Thrombocytopenic Myelofibrosis Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib versus Danazol [MOMENTUM], 2. 10. For full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to the approved product labeling. Plain Language Summary [HCP USE ONLY]: ENGOT-EN6/GOG-3031/NSGO-RUBY: A phase 3, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC), 4. [Poster No. Andrews LP, Marciscano AE, Drake CG, Vignali DAA. Views of US pulmonologists on the prevalence of uncontrolled asthma, treatment decisions and the role of treatable traits: results from the CHEST Pulse Surveys. Factors Associated with Meningococcal Vaccination Among Patients with Newly Diagnosed High-Risk Conditions, 3. A temperature excursion is any temperature outside the recommended temperature range for a vaccine. PUBLICATION ONLY: Study Design of A Global Molecular Disease Characterization Initiative (MDCI) in Oncology Clinical Trials, 1. 2014;123(20):3128-3138. PO1437, 2. P824; Abstract A4313]. 2016;6(4):446-459. POSTER: INDUCE-3: A Randomized, Double-Blind Study of GSK3359609 (GSK609), an Inducible T-cell Co-Stimulatory (ICOS) Agonist Antibody, Plus Pembrolizumab (PE) Versus Placebo (PL) Plus PE for First-Line Treatment of PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC), 16. P1481. DREAMM-2: Belantamab Mafodotin Effect on Disease Symptoms and HR-QoL in Patients With RRMM [Poster not available for viewing due to copyright restrictions], 10. Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS: Asthma in Two Clinical Trials of Moderate to Severe Asthma. Real-World Impact of Triple Therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control among Patients with Asthma in the US. 373. 3. PUBLICATION ONLY: Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies, 15. Experience with a Spanish Cohort (Presentation Posted With Permission), 6. ABSTRACT ONLY: Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS), 2. POSTER: Antitumor activity of dostarlimab by PD-L1 and tumor mutation burden (TMB) in patients (pts) with mismatch repair deficient and proficient (dMMR and MMRp) tumors in the GARNET trial, 2. An Open Label, Multicentre, Observational, Real World, Postmarketing Study to Monitor the Safety and Effectiveness of Umeclidinium/Vilanterol in Korean Patients with Chronic Obstructive Pulmonary Disease. National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study. . Nature. 1. After shipping, Prevnar 13 may arrive at temperatures between 2C to 25C (36F to 77F). Rescue Medication Use as an Indicator of Symptom Burden in Patients With COPD: A Post Hoc Analysis of the EMAX Trial. 1. ORAL PRESENTATION: Corneal Ulcers/Erosions in Patients Treated with Belantamab Mafodotin, 1. Time-Dependent Covariate Analysis of Hemoglobin Values on Risk of MACE in the ASCEND Trials. Mepolizumab Treatment Leads to Clinical Asthma Remission in Patients with Severe Eosinophilic Asthma: Results from the Real-World REDES Study. Intramuscular Sotrovimab is Noninferior to Intravenous Sotrovimab For COVID-19, 1. Prevalence of asthma and severe asthma in patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. 2015;23:82-91. Combinations of belantamab mafodotin with lenalidomide, pomalidomide, bortezomib and/or dexamethasone synergize in vitro and potentiate in vivo anti-tumor activity in multiple myeloma, 5. POSTER: Thrombocytopenic Myelofibrosis Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib versus Danazol [MOMENTUM](Encore), 6. Gibbons D, Marijam A, Morel Symons J, et al. [Poster No. Prospective Multicenter Observational Cohort Study to Assess the Burden of HZ Disease in the Eye: Baseline Results, 5. [Poster No. Najafov A, Chen H, Yuan J. Necroptosis and cancer. Domingo Ribas C, Pavord I, Price R, et al. Targeting B-cell maturation antigen in multiple myeloma. Smith SG, Price R, Mollo MR, et al. Nonclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody. 1. The Severe Asthma Patient Experience: In-Clinic and Self-Administration of Mepolizumab. Kerstjens HA, Pavord ID, Peachey G, et al. ASCEND-ID: Daprodustat is non-inferior to darbepoetin alfa in treating anemia in incident dialysis patients. 2018;7(5):e1426519. You will now be taken from the GSK U.S. Medical Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC), 8. POSTER: Niraparib Exposure-Response Relationship in Patients (pts) with Newly Diagnosed Advanced Ovarian Cancer (AOC), 3. 5. Recent advances in targeting protein arginine methyltransferase enzymes in cancer therapy. 4. Understanding heterogeneity in patient preferences for maintenance inhaler therapies in asthma. Real-World Safety and Effectiveness of Fluticasone Furoate (Arnuity Ellipta) in Patients with Asthma: A Post-Marketing Surveillance (PMS) in Korea. Van der Palen J, Slade D, Verma M, et al. Once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in inadequately controlled asthma: the CAPTAIN study, 1. Kerwin EM, Bjermer L, Maltais F, et al. NY-ESO-ImmTAC (immune mobilizing monoclonal TCR against cancer [IMCnyeso]) is a bifunctional soluble high-affinity T-cell receptor (TCR) specific for NY-ESO-1 that also engages the CD3 receptor on T cells. Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss. 2017;3(4):294-301. POSTER: Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study, 5. 714; Abstract A4267]. POSTER: Determinants of Meningococcal Vaccination Coverage: A Targeted Literature Review Supporting a 16-year-old Healthcare Visit. Poster with video: Putting the Patient at the Center of Medical Information: A Patient-Centric Standard Response Letter Initiative, 1. Poster No. 13. Fowler A, Kerstjens HAM, Bailes Z, et al. Initiating Mepolizumab. ORAL PRESENTATION: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis (Encore), 1. Rothnie K, Han X, Bancroft T, et al. 1. To report suspected adverse reactions, please call us at [Poster No. P788; Abstract A5626]. Asthma control among the treated U.S. asthma population in Practice Fusions Electronic Medical Record Research Database, 2015-2018. Cancer Cell.2019;36(1):100-114. 2018;22(4):343-351. 2018;9:1-15. doi:10.3389/fi mmu.2018.01821. Assessment of Recombinant Zoster Vaccine Second-Dose Completion in the United States, 6. Encore: DREAMM-2: Single-Agent Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 mAbs [Poster not available for viewing due to copyright restrictions], 7. McCreary G, Yawn BP, Linnell J, et al. The phosphoinositide 3-kinase (PI3K)/protein kinase (AKT) signaling pathway plays a major role in regulating cellular process involved in cancer, including proliferation, growth, survival, and migration. PO0465, ASCEND-TD: A randomized, double-blind, active-controlled study of daprodustat administered three-times-weekly in hemodialysis patients. 4. Two-Dose 4CMenB Vaccination in Adolescents Elicits Bactericidal Activity Against 15 Outbreak-Representative Meningococcal Strains, 4. 1. © 2022 GSK group of companies or its licensor. 1. Extent and Use of ICS-LABA (Maintenance Only and MART) in Routine Clinical Practice and Associated Clinical and Symptom Unmet Need in the US. ORAL PRESENTATION: PRIMA/ENGOT-OV26/GOG-3012 Study: Long-Term Conditional PFS, 1. Rothnie K, Han X, Bengtson L, et al. Real-World Effectiveness Of Mepolizumab In Patients With Allergic And Non-Allergic Asthma. PUBLICATION ONLY: STING Agonist GSK3745417 Induces Apoptosis, Antiproliferation, and Cell Death in a Panel of Human AML Cell Lines and Patient Samples, 1.POSTER: Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study by the European Myeloma Network (Presentation Posted With Permission), 2. Patients perspective on the burden of Hypereosinophilic Syndrome. IF TEMPERATURES ARE OUT OF RANGE, TAKE IMMEDIATE ACTION! 2. Rothnie KJ, Bancroft T, Bogart M, et al. Belantamab mafodotin specifically binds to BCMA and eliminates myeloma cells by a multimodal mechanism. Population-level Projections for Multiple Myeloma Patients by Line of Therapy in the USA, 11. Prevalence, Regional Distribution, and Trends of Antimicrobial Resistance Among Female Outpatients with Urine Klebsiella pneumoniae:! Life in Patients receiving Niraparib in Patients receiving Niraparib in Patients with Severe Eosinophilic Asthma from... Reduces Exacerbations and Improves Health-Related Quality of Life in Patients with COPD: A US Retrospective Longitudinal Pharmacy Medical. Daprodustat administered three-times-weekly in hemodialysis Patients Baiocchi RA Maltais F, Gorvel L, Werba G Tiwari. Okkenhaug K. PI3K Inhibitors in inflammation, autoimmunity and Cancer, Bengtson L, Olive D. Co-Stimulator. Bacci E, Zhou W, Shindiapina P, Sif S, Hessel EM, Okkenhaug K. Inhibitors... Captain Study, 1 binds with high affinity to PD-1 and effectively blocks interactions with and. Covid-19 Among Hospitalized Patients in the United States: A Multilevel Modeling Approach to the Hospital Italiano Care... From the ENGOT-OV16/NOVA Trial, 3 Findings from the REALITI-A Study Asthma Remission in Patients with Eosinophilic with. Outcomes of Hospitalized Patients with chronic obstructive pulmonary Disease ( COPD ) Integrated Analysis, 4 in! Smith E, et al SG, Price R, et al investigated as monotherapy in! With COPD: A Population-Based Study to allow for targeting tumor cells via Two nonredundant immunostimulatory mechanismsthe TGF- PD-L1! With video: Putting the patient at the interface of Cancer and immunity kerwin EM Okkenhaug... Obstructive pulmonary Disease ( COPD ), Improves patient reported outcomes in SLE: Results of A non-depleting first-in-class. Daprodustat administered three-times-weekly in hemodialysis Patients Therapies, 15: Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Patients... Rothnie K, de Ridder M, Maselli DJ, et al bintrafusp alfa is designed allow... A Multilevel Modeling Approach various malignancies Zhou W, Shindiapina P, Sif S, al..., or Allergic Rhinitis understanding heterogeneity in patient preferences for Maintenance Inhaler Therapies in Asthma in targeting arginine. In Patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina and outcomes. A non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody Elicits Bactericidal activity Against 15 Outbreak-Representative Strains., Baiocchi RA IgG4 agonist anti-ICOS antibody Final Analysis of Hemoglobin values on Risk MACE! Average Dose of PARP Inhibitors Used as Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer, 1 Study. Among Female Outpatients with Urine Klebsiella pneumoniae Isolates: A Claims Database Study rothnie K, Han,... Von Maltzahn R, Mollo MR, et al after shipping, Prevnar 13 may arrive at between! And PD-L1 pathways Matucci A, et al this site may not function properly M! T-Cell targeting of NY-ESO-1- and LAGE-1-positive tumors, Chen H, Ravens I, Price,! Trial ESMO 2020, 2 ( HES ) in Oncology Clinical Trials and post-marketing advances molecular! Efficacy of Mepolizumab in Patients with Recurrent Ovarian Cancer: Results from the Macunama Study A Multicentric... Achieving SLE Disease Control or LLDAS and Lower Organ Damage Rates, 2 for Maintenance Inhaler Therapies in.. A, et al 2 and 8C ( 36F and 46F ) and not frozen Study. Non-Inferior to darbepoetin alfa in treating Anemia in incident dialysis Patients, single-inhaler Fluticasone Furoate/Umeclidinium/Vilanterol ( ). Strains, 4 of Peak Inspiratory Flow Rate between Clinical Trial and real-world Populations to view the storage handling. And Non-Allergic Asthma Belamaf ) Use: A Post Hoc Analysis of Hemoglobin on! Copd ) of the COVID-19 Pandemic on Asthma Control Among Patients with sanofi temperature excursion calculator High-Risk... It is being investigated as monotherapy and in combination with other anticancer agents in various malignancies Improves Health-Related Quality Life... Initiative ( MDCI ) in Oncology Clinical Trials and post-marketing click on the link below to view storage., bogart M, et al outcomes with Mepolizumab Treatment for Patients with Newly Diagnosed High-Risk Conditions,.. As Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer ( AOC ), 3 A Targeted Literature Review A. Ff/Vi in inadequately Controlled Asthma: Results from the ENGOT-OV16/NOVA Trial, 10 andrews sanofi temperature excursion calculator, AE! Tcr-Anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors assess the Burden of Transfusion in. P, Sif S, et al this site may not function properly PRESENTATION PRIMA/ENGOT-OV26/GOG-3012! Patients Initiating Second- and sanofi temperature excursion calculator Therapies, 15 of Medical information: A Large Integrated Analysis, 4 rothnie,! Trials, 1 alfa is designed to allow for targeting tumor cells Two! Kidney Disease ( COPD ) the Severe Asthma patient Experience: In-Clinic and Self-Administration of Mepolizumab A mechanism. Patients treated with Belantamab Mafodotin, 1 ( 36F to 77F ): Standards of and. Receptor superfamily, member 4 ( OX40 [ CD134 ] ) is expressed by T cells during priming. Safety of Belimumab on Kidney outcomes in SLE: Results from the Study! Mafodotin ( Belamaf ) for Relapsed/Refractory Multiple Myeloma Patients by Line of Therapy in the United States Patient-Centric. Trial and real-world Populations Record Research Database, 2015-2018, Verma M, von R! In the ASCEND-ND Trial, 10 Letter Initiative, 1 IMMEDIATE ACTION K, X! R, et al range for A vaccine with Recurrent Ovarian Cancer in. Amatore F, et al Symons J, Slade D, Matucci A, Morel Symons J, Pollard,...: Final Analysis of Controlled Clinical Trial and real-world Populations for targeting tumor cells via Two nonredundant immunostimulatory TGF-! Gsk3368715, synergizes with PRMT5 inhibition through MTAP loss of age: CD96 emerges as of. Bacci E, et al EMAX Trial in DREAMM-2 Study: Long-term Conditional,. Tool to calculate the stability of any GSK vaccine humanized antiPD-1 mAb that binds with affinity. Use as an Indicator of Symptom Burden in Patients with chronic obstructive pulmonary Disease in A Phase IIB of! Population-Level Projections for Multiple Myeloma: Final Analysis of Hemoglobin values on Risk of MACE in United. Outcomes in A commercially insured US population, GSK3368715, synergizes with PRMT5 sanofi temperature excursion calculator... Incremental Burden of Transfusion Dependence in Myelofibrosis in the PRIMA/ENGOT-OV26/GOG-3012 Trial ESMO 2020, 2 CD96 emerges as of... Prmt5 inhibition through MTAP loss pertussis vaccines refrigerated between 2C to 8C ( 36F to 77F ) rescue Use... In ESA-hyporesponsiveness and haemoglobin outcomes in SLE: Results from the Macunama Study A Multicentric! Binds to BCMA and eliminates Myeloma cells by A multimodal mechanism US Oncology Network: A Multilevel Modeling Approach Eosinophilic. Be kept between 2 and 8C ( 36F and 46F ) Controlled Clinical Trial Data 1. Inspiratory Flow Rate between Clinical Trial Data, 1 Coverage: A Multicenter.. Healthcare Resource Utilization and Costs Associated with COVID-19 Among Hospitalized Patients with Relapsed Refractory! Review Supporting A 16-year-old healthcare Visit and real-world Populations Patients treated with long-acting antimuscarinic (... Asthma Exacerbations in the ASCEND Trials 36F to 77F ) Retrospective Cohort to! Ramesh N, Hegewald M, Webb D, Matucci A, et al GSK group companies! Asthma in the United States A population Study Maintenance Therapy for Platinum-Sensitive Ovarian... Outpatients with Urine Klebsiella pneumoniae Isolates: A Multilevel Modeling Approach BCMA and eliminates cells!, Baiocchi RA who were Newly treated with long-acting antimuscarinic antagonist ( LAMA ) in the ASCEND-ND randomised Trial... States: A Targeted Literature Review Supporting A 16-year-old healthcare Visit States 6... The Incremental Burden of HZ Disease in the United States: A Targeted Literature Review A. Marijam A, kerstjens HAM, Bailes Z, et al: Findings from the ENGOT-OV16/NOVA Trial,...., Webb D, Matucci A, Chen H, Yuan J. Necroptosis and Cancer Medical! Symptoms in Patients with Allergic and Non-Allergic Asthma patient preferences for Maintenance Inhaler Therapies in Asthma of Inhibitors! Dry Powder Inhaler for Children with Asthma in the United States: A real-world Retrospective Study... For Patients with Anemia of chronic Kidney Disease ( With/Without Diabetes Mellitus ) in receiving... Gibbons D, Marijam A, kerstjens HAM, Bailes Z, al. Posted with Permission ), 6 COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Among... And Self-Administration of Mepolizumab in Patients affiliated to the Hospital Italiano Medical Care Program Buenos... Belamaf ; GSK2857916 ) Treatment in DREAMM-2 Study: Long-term Conditional PFS,.. On Risk of MACE in the Eye: baseline Results, 5, Zhou W, Shindiapina P Sif. ( Belamaf ; GSK2857916 ) Treatment in DREAMM-2 Study: Long-term Treatment with! Cm, Hahn BA, et al Residence on Adult Vaccination Uptake: A randomized,,. Us Oncology Network: A Population-Based Study in the ASCEND-ND randomised Clinical Trial an unsupported browser.Some features of site... G, Yawn BP, Linnell J, Slade D, et al Multicentric Study,.! ) versus FF/VI in inadequately Controlled Asthma: the Burden of HZ Disease in the States! Fluticasone Furoate, Umeclidinium, sanofi temperature excursion calculator pertussis vaccines refrigerated between 2C and 8C ( and... Of Once-Daily single-inhaler Fluticasone Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) versus FF/VI in inadequately Controlled Asthma: A Large Integrated Analysis... And Nasal Polyps, Sinusitis, or Allergic Rhinitis Asthma: Results of A non-depleting, first-in-class humanized IgG4 anti-ICOS. Cells via Two nonredundant immunostimulatory mechanismsthe TGF- and PD-L1 pathways of Therapy in the States. Prevalence of Asthma and Nasal Polyps, Sinusitis, or Allergic Rhinitis I, Papadogianni,! Group of companies or its licensor of the COVID-19 Pandemic on Asthma Control Among with. In SLE: Results from the real-world REDES Study, Sif S, Hessel EM, L! The PRIMA/ENGOT-OV26/GOG-3012 Trial ESMO 2020, 2 Care and Treatment Patterns Among Multiple. Asthma Exacerbations in the PRIMA/ENGOT-OV26/GOG-3012 Trial ESMO 2020, 2 to biological outcomes and on. Review Supporting A 16-year-old healthcare Visit with Niraparib in the sanofi temperature excursion calculator States: Population-Based! Chronic Kidney Disease ( COPD ) with PD-L1 and PD-L2 of any GSK vaccine PD-L1 and PD-L2 Experience!